Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/60475
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHallinan, R.en
dc.contributor.authorCrettol, S.en
dc.contributor.authorAgho, K.en
dc.contributor.authorAttia, J.en
dc.contributor.authorBesson, J.en
dc.contributor.authorCroquette-Krokar, M.en
dc.contributor.authorHammig, R.en
dc.contributor.authorDeglon, J.en
dc.contributor.authorByrne, A.en
dc.contributor.authorRay, J.en
dc.contributor.authorSomogyi, A.en
dc.contributor.authorEap, C.en
dc.date.issued2009en
dc.identifier.citationEuropean Journal of Clinical Pharmacology, 2009; 65(11):1113-1120en
dc.identifier.issn0031-6970en
dc.identifier.issn1432-1041en
dc.identifier.urihttp://hdl.handle.net/2440/60475-
dc.description.abstractPurpose: To assess tobacco, alcohol, cannabis and benzodiazepine use in methadone maintenance treatment (MMT) as potential sources of variability in methadone pharmacokinetics. Methods: Trough plasma (R)- and (S)-methadone concentrations were measured on 77 Australian and 74 Swiss MMT patients with no additional medications other than benzodiazepines. Simple and multiple regression analyses were performed for the primary metric, plasma methadone concentration/dose. Results: Cannabis and methadone dose were significantly associated with lower 24-h plasma (R)- and (S)-methadone concentrations/dose. The models containing these variables explained 14–16% and 17–25% of the variation in (R)- and (S)-methadone concentration/dose, respectively. Analysis of 61 patients using only CYP3A4 metabolised benzodiazepines showed this class to be associated with higher (R)-concentration/dose, which is consistent with a potential competitive inhibition of CYP3A4. Conclusion: Cannabis use and higher methadone doses in MMT could in part be a response to—or a cause of—more rapid methadone clearance. The effects of cannabis and benzodiazepines should be controlled for in future studies on methadone pharmacokinetics in MMT.en
dc.description.statementofresponsibilityRichard Hallinan, Séverine Crettol, Kingsley Agho, John Attia, Jacques Besson, Marina Croquette-Krokar, Robert Hämmig, Jean-Jacques Déglon, Andrew Byrne, John Ray, Andrew A. Somogyi, Chin B. Eapen
dc.language.isoenen
dc.publisherSpringeren
dc.rights© Springer-Verlag 2009en
dc.subjectBenzodiazepine; Cannabis; Drug interaction; Enantiomer; Methadone; MMT; Pharmacokineticsen
dc.titleCannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational studyen
dc.typeJournal articleen
dc.identifier.rmid0020091529en
dc.identifier.doi10.1007/s00228-009-0706-8en
dc.identifier.pubid38271-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.